Literature DB >> 27548347

Renal cell cancer: overview of the current therapeutic landscape.

Mustafa Erman1, Mustafa Benekli2, Mert Basaran3, Sevil Bavbek4, Suleyman Buyukberber2, Ugur Coskun2, Gokhan Demir5, Bulent Karabulut6, Berna Oksuzoglu7, Metin Ozkan8, Alper Sevinc9, Suayib Yalcin10.   

Abstract

INTRODUCTION: The last decade has witnessed dramatic improvements in the diagnosis, classification and treatment of renal cell cancer (RCC). Besides improvements in surgical techniques in early stages, introduction of novel targeted agents has resulted in improved outcomes in advanced RCC for which no effective treatment existed until recently. AREAS COVERED: This article reviews epidemiology, pathology and pathogenesis, diagnosis, clinical staging, prognostic factors and treatment modalities of early stage and advanced RCC. Expert commentary: Although treatment options are expanding rapidly, practicing physicians face considerable challenges in the decision-making process. Therapeutic agents may have unique side effects and unexpected drug interactions. RCC represents one of the major success stories of clinical oncology in recent years and the progress appears to be far from having reached a plateau. We aim to present a comprehensive in-depth review of RCC in an attempt to provide evidence-based recommendations and future perspectives for practicing oncologists.

Entities:  

Keywords:  Renal cell cancer; classification; diagnosis; targeted therapies; treatment

Mesh:

Substances:

Year:  2016        PMID: 27548347     DOI: 10.1080/14737140.2016.1222908

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  8 in total

1.  Induction of endoplasmic reticulum stress and mitochondrial dysfunction dependent apoptosis signaling pathway in human renal cancer cells by norcantharidin.

Authors:  Min-Hua Wu; Hui-Ling Chiou; Chu-Liang Lin; Ching-Yi Lin; Shun-Fa Yang; Yi-Hsien Hsieh
Journal:  Oncotarget       Date:  2017-12-19

2.  Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients.

Authors:  Chiara Massa; Harlan Robins; Cindy Desmarais; Dagmar Riemann; Corinna Fahldieck; Paolo Fornara; Barbara Seliger
Journal:  Oncotarget       Date:  2017-03-28

3.  Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation.

Authors:  Vera Miranda-Gonçalves; Ana Lameirinhas; Catarina Macedo-Silva; João Lobo; Paula C Dias; Verónica Ferreira; Rui Henrique; Carmen Jerónimo
Journal:  Cells       Date:  2020-04-23       Impact factor: 6.600

Review 4.  The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma.

Authors:  Ana Lameirinhas; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo
Journal:  Genes (Basel)       Date:  2019-04-02       Impact factor: 4.096

Review 5.  Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.

Authors:  Nanna Bæk Møller; Cecilie Budolfsen; Daniela Grimm; Marcus Krüger; Manfred Infanger; Markus Wehland; Nils E Magnusson
Journal:  Int J Mol Sci       Date:  2019-09-23       Impact factor: 5.923

6.  Effects of Curcumin Analogues DMC and EF24 in Combination with the Cytokine TRAIL against Kidney Cancer.

Authors:  Verónica Ibáñez Gaspar; Jasmin McCaul; Hilary Cassidy; Craig Slattery; Tara McMorrow
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

7.  Long non-coding RNA ARAP1-AS1 contributes to cell proliferation and migration in clear cell renal cell carcinoma via the miR-361-3p/placental growth factor axis.

Authors:  Liping Zhong; Xiuwen Zhong
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma.

Authors:  Suayib Yalcin; Sahin Lacin
Journal:  Cancer Manag Res       Date:  2019-08-16       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.